( H ) Intracellular cAMP accumulation in human caSMCs treated with the sAC inhibitor KH7 (25 M, dark gray bars), the tmAC inhibitor Ddox (50 M, white bars), or PBS (light gray bars) for 3 hours followed by a 15-minute treatment with GLP-1(2836), scrambled control, IPE, or forskolin
This allows for dose adjustments if thyroid hormone levels shift outside the target range
*Average weight loss based on 68 and 72 week clinical trials studying semaglutide (2.4 mg) and tirzepatide (10-15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related health condition, the average weight loss was 15% and 20% respectively
Additionally, this test addresses liver hormone detoxification challenges, potentially increasing the risk of developing various cancers and diseases
The semaglutide component follows the same dose escalation schedule as standard compounded semaglutide: Weeks 1-4: 0.25 mg semaglutide (0.1 mL) Weeks 5-8: 0.5 mg semaglutide (0.2 mL) Weeks 9-12: 1.0 mg semaglutide (0.4 mL) Weeks 13-16: 1.7 mg semaglutide (0.68 mL) Week 17+: 2.4 mg semaglutide (0.96 mL) The niacinamide dose scales proportionally with the injection volume
At The WellSpa, we value comprehensive patient care which includes staying informed about the latest advancements in medication and treatment options